Predictive Oncology Inc (POAI) concluded trading on Wednesday at a closing price of $1.48, with 48.29 million shares of worth about $71.46 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 38.32% during that period and on January 22, 2025 the price saw a gain of about 16.54%. Currently the company’s common shares owned by public are about 6.67M shares, out of which, 6.52M shares are available for trading.
Stock saw a price change of 23.33% in past 5 days and over the past one month there was a price change of 102.74%. Year-to-date (YTD), POAI shares are showing a performance of 80.49% which decreased to -49.83% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.55 but also hit the highest price of $3.76 during that period. The average intraday trading volume for Predictive Oncology Inc shares is 1.18 million. The stock is currently trading 28.36% above its 20-day simple moving average (SMA20), while that difference is up 61.46% for SMA50 and it goes to 37.53% higher than SMA200.
Predictive Oncology Inc (NASDAQ: POAI) currently have 6.67M outstanding shares and institutions hold larger chunk of about 3.03% of that.
The stock has a current market capitalization of $9.87M and its 3Y-monthly beta is at 1.24. It has posted earnings per share of -$3.06 in the same period. It has Quick Ratio of 1.06 while making debt-to-equity ratio of 1.22. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for POAI, volatility over the week remained 27.05% while standing at 27.46% over the month.
Analysts are in expectations that Predictive Oncology Inc (POAI) stock would likely to be making an EPS of 0 in the current quarter, while forecast for next quarter EPS is 0 and it is 0 for next year. For the current quarter EPS, analysts have given the company a lowest target 0 which is 0 at the higher side of the target for the same. Stock’s fiscal year EPS is expected to rise by 40.23% while it is estimated to increase by 93.75% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on August 19, 2024 offering a Buy rating for the stock and assigned a target price of $3 to it.
